Lupin Limited announced a strategic collaboration with TB Alliance, a nonprofit drug development organisation, to support the clinical advancement and commercialization of Telacebec (previously known as Q203). The investigational therapy is being developed for the treatment of tuberculosis (TB) and other mycobacterial diseases, including leprosy and Buruli ulcer. Under the agreement, TB Alliance will continue to lead the development programme, while Lupin will contribute its capabilities across manufacturing scale-up, regulatory strategy, and global supply chain execution, with the goal of enabling broader access to Telacebec.
“This collaboration reinforces Lupin’s long-standing focus on improving care in areas where treatment options remain limited,” said Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin. “By combining Lupin’s manufacturing strength and global reach with TB Alliance’s scientific leadership, we aim to support timely and equitable availability of Telacebec for people affected by TB, leprosy, and Buruli ulcer.”
Mel Spigelman, MD, President and CEO, TB Alliance, said, “Telacebec represents a meaningful step forward in innovation for diseases that have historically received far too little attention. Through this partnership with Lupin, we are joining TB Alliance’s scientific expertise with Lupin’s Chemistry, Manufacturing and Controls capabilities and global access strengths to progress this compound responsibly and as efficiently as possible—ultimately improving treatment options for patients worldwide.”
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed across more than 100 markets. The company’s portfolio includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Lupin has strong positions in India and the U.S. in several therapeutic areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. The organisation operates 15 manufacturing facilities and 7 R&D centres globally, supported by a workforce of more than 24,000 professionals. Lupin continues to expand healthcare impact through its subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
TB Alliance is a not-for-profit organisation focused on developing faster-acting and affordable drug regimens for TB and related mycobacterial diseases such as leprosy and Buruli ulcer. Through scientific innovation and global partnerships, TB Alliance works to improve access to better cures that strengthen global health outcomes.
TB Alliance is supported by a wide network of global funding partners including Australia’s Department of Foreign Affairs and Trade, Cystic Fibrosis Foundation, the UK Foreign, Commonwealth & Development Office, Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR) through KfW, Global Disease Eradication Fund (South Korea), Global Health Innovative Technology Fund, Korea International Cooperation Agency, MedAccess, Raoul Follerau Foundation, South Korea’s Ministry of Foreign Affairs, US Department of Defense CDMRP, US Department of State, US NIH NCATS, US NIH NIAID, and Unitaid.